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Abstract 
Background:Parenteral nutrition (PN) is a treatment that supplies one's nutrition and hydration 
needs intravenously. Intravenous soybean lipid emulsions have been associated with Parenteral 
Nutrition Associated Liver Disease (PNALD), due to its high phytosterol content and high n-6:n-
3 ratio and its propensity to mitigate inflammatory eicosanoid pathways. Composed of soybean 
oil, medium chain fatty acids, olive oil, and fish oil, Smoflipid may ameliorate PNALD and 
mitigate anti-inflammatory eicosanoid pathways. 
Objective: To examine the effectiveness of Smoflipid on improving liver function and bilirubin 
levels on home PN-dependent children with intestinal failure related PNALD. 
Design: A prospective electronic medical record review was conducted from 2016-2018 at Loma 
Linda University Children’s Hospital (LLUCH).  
Participants: Charts of thirteen outpatient children (8.1±4.2 years, 6 females and 7 males) with 
intestinal failure who either have completed six-months of Smoflipid or are currently taking 
Smoflipid. 
Main outcomes: Preventing or reducing the severity of PNALD. 
Secondary outcomes: Sustaining growth, reducing TPN infection rates and measuring Smoflipid 
tolerance by assessing essential fatty acid status, fasting glucose levels, hemoglobin A1C, total 
cholesterol, and serum triglycerides. 
Statistics: A Mixed Model was used to account missing values and measure changes in 
continuous variables. Values were summarized by calculating the mean and standard deviation, 
before and after Smoflipid treatment. 
Results: Although there was a decreasing trend in ALT (N=11, 23.2% after six-months) and AST 
(N=11, 8.3% after six-months), Smoflipid did not have a statistical significant impact on ALT, 
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AST, and total bilirubin. There was a significant impact on central line infection rates (n= 5, 
p=0.032) and hemoglobin A1C (n=3, p=0.001).  
Conclusion: Smoflipid may yield biochemical effects in reducing elevated liver enzymes 
associated with PNALD and enhance the quality of life by improving liver function, sustaining 
growth, and reducing infection rates, and hemoglobin A1C. Smoflipid may be a beneficial 
alternative to the standard soybean-based lipid emulsion. 
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 Introduction 
Intestinal failure (IF) is a medical condition characterized by the inability of the 
gastrointestinal (GI) tract to absorb all of the nutrition and fluids needed for normal physiologic 
function, growth, and/or development.1 The causes of IF are many, including short bowel 
syndrome, gastroschisis, congenital intestinal abnormalities, and trauma.2 Until the 1960’s and 
1970’s, most patients with intestinal failure died because there was no means to provide patients 
with appropriate nutrition and hydration.3 The dual inventions of the central venous catheter and 
the parenteral nutrition dramatically changed the long-term outlook for patient with IF.4 
Parenteral nutrition (PN) is a medical treatment in which 100% of a patient’s nutrition and 
hydration needs can be provided by daily infusion of a customized intravenous solution. The 
solution generally includes pharmaceutical-grade carbohydrates, proteins, fats, micronutrients 
and water that are required for normal physiologic function and growth.3 The almost 
simultaneous production of long term indwelling central venous catheter, such as the Hickmann 
and Broviac catheters, afforded the infusion of parenteral nutrition.3 
Parenteral nutrition is frequently employed in pediatric and adult care in both, acute and 
long-term settings. To many, total parenteral nutrition (TPN) is an alternative prolonged 
hospitalization.5-6 More specifically, within the pediatric setting, PN is utilized in intestinal 
disorders, such as intestinal failure and Short Bowel Syndrome.7 While some children are 
capable of oral intake, PN may be necessary to supplement the diet due to the intestine’s 
impaired ability to absorb nutrients from food.8 
A typical PN formula is composed of dextrose, amino acids and lipid emulsions.1 Lipid 
emulsions are “biologically vital” because they serve as a high-energy supply, deliver essential 
fatty acids (EFA) that can not be endogenously synthesized, and protect against high glucose 
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infusion rates.7 A high glucose infusion rate may lead to complications such as hyperglycemia 
and hepatic steatosis.7The main component of PN lipid emulsions is soybean oil. In the United 
States, pure soybean oil lipid emulsions (Lyposyn III and Intralipid) are the dominant fat source 
in PN.5 Soybean oil is abundant in two essential fatty acids (EFA), linoleic acid (LA) and alpha 
linolenic acid (ALA), and has been effective in preventing EFA deficiencies.8 Despite this 
success, there are some concerns with both the high phytosterol content and the n-6:n-3 ratio of 
this emulsion.9 
One concern pertaining to the use of soybean-based lipid emulsion in PN is attributed to 
its high phytosterol content. Phytosterols are plant-based and biologically similar to cholesterol. 
However, the human body cannot metabolize phytosterols.10 Through enteral nutrition, the 
intestine only absorbs 5% of phytosterols.10 However, administration via PN enables 100% 
uptake of phytosterol into circulation. This can accumulate in the liver and bile, which could 
ultimately lead to phytosterol-mediated cholestasis and liver injury.10-11 
Another concern involves the high proportion of n-6:n-3 ratio and its capacity to induce 
inflammation and hepatotoxicity.5 LA is part of the n-6 fatty acid (FA) family that are 
proinflammatory eicosanoid precursors of prostaglandin series-2 and leukotrienes series-4.12-13 
Conversely, ALA, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) belong to the 
n-3 FA family. These fatty acids are anti-inflammatory eicosanoid precursors for the 
prostaglandin series-3, leukotriene series-5, resolvins, protectins and maresins.12-13 Research 
proposes that diets higher in n-6 (proinflammatory), in relation to n-3 (anti-inflammatory), 
correlate with higher proinflammatory markers in serum levels and enhances thrombin-mediated 
platelet aggregation.14-15 Thus, soybean oil-based emulsions raise a concern for its use in PN 
because of its high n-6 content and its propensity to mitigate proinflammatory pathways. In 
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addition, recent findings suggest that high amounts of n-6 FA instigate lipid peroxidation.16This 
volatile reaction results in the production of reactive oxygen species (ROS) and additional pro-
inflammatory markers (cytokines).16  In all, high phytosterols and high n:6-n:3 ratios in the 
soybean-based lipid emulsion can promote inflammatory states and damage vital organs and 
tissues. 
The liver is highly vulnerable to lipid peroxidation. Long-term parenteral feedings can 
lead to severe complications such as Parenteral Nutrition Associated Liver Disease (PNALD).16-
17 PNALD is an umbrella term for three types of hepatobiliary disorders associated with PN: 
steatosis, cholestasis and gallbladder stasis.16-17 Steatosis is identified by mild to moderate levels 
of serum aminotransferase levels with less pronounced elevations of serum alkaline phosphatase 
and bilirubin concentrations.17 Cholestasis refers to an impaired secretion of bile or a biliary 
obstruction, as evidenced by elevated serum concentrations of alkaline phosphatase, 
aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase 
(GGT) and conjugated bilirubin concentrations.17 Lastly, gallbladder stasis results from lack of 
oral intake. Decreased release of cholecystokinin (CCK) impairs bile flow and contraction of the 
gallbladder which results in biliary sludge and gallstones.17Thus, PNALD is detrimental because 
steatosis, cholestasis and gallbladder sludge may lead to fibrosis, cirrhosis and liver failure.6PN-
dependent children and infants may be more susceptible to liver damage due to age-related 
hepatic immaturity.18-19 Treatment options for these conditions are limited and individuals with a 
weak immunity are highly vulnerable to mortality.18 
Smoflipid is a balanced lipid profile composed of 30% soybean oil (n-6), 30% medium 
chain fatty acids, 25% olive oil and 15% fish oil (n-3, EPA and DHA).20 To address PNALD, 
Smoflipid was designed to lower the n:6-n-3 ratio and phytosterol content.9In doing so, this may 
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reduce lipid peroxidation and prevent further damage to the liver. Compared to the standard 
soybean lipid emulsion, Smoflipid contains less phytosterol (∼50 mg/L) and more α-tocopherol 
(∼200 mg/L).5 The previous soybean lipid emulsion had a 7:1 n-6:n-3 ratio.16 As Smoflipid 
yields a n-6:n-3 ratio of 2.5:1, this lowers the ratio and improves the overall n-6:n-3 ratio.20-21 A 
higher n-3 fatty acids content facilitates in mitigating anti-inflammatory eicosanoid pathways.8 
An increasing body of evidence from Fell et al.,5 Calder et al.16, Saayman et al.,18 Rayyan et al.,19 
Canada et al.,20 Tomsits et al.,21 and Goulet et al.22 support the use of Smoflipid in preventing or 
reducing the severity of PNALD.5,16,18-22 Short-term trials suggest that Smoflipid has been 
deemed safe and well-tolerated in preterm infants.20 Results from another short-term randomized 
clinical control trial exhibited improved liver function (bilirubin and γ-glutamyl transferase) with 
Smoflipid, compared to the standard soybean lipid emulsion.21-22 Another small retrospective 
cohort study examined children who developed PNALD from a soybean lipid emulsion and were 
treated with Smoflipid.18 In 5 out of the 8 children, results exhibited improvements in 
cholestasis.17 Thus, the usage of Smoflipid in preventing PNALD has been shown to be favorable 
in early clinical trials. In addition to the possible protective effects on the liver, other areas of 
interest include evaluating the effects of Smoflipid on sustaining growth, reducing TPN central 
line infection rates, supplying essential fatty acid requirements and overall tolerance through 
monitoring lab values of serum triglycerides, total cholesterol, fasting glucose and hemoglobin 
A1C. As Smoflipid is a new treatment, it may be a beneficial alternative to the standard soybean 
lipid emulsion in pediatric patients with intestinal failure related PNALD. 
The purpose of this prospective observational graduate student research study was to 
examine the effectiveness of Smoflipid on improving liver enzymes (AST, ALT) and total 
bilirubin levels on home TPN-dependent pediatric patients with intestinal failure related 
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parenteral nutrition associated liver disease (PNALD). Secondary outcomes examined Smoflipid 
and its effect on sustaining growth, reducing TPN central line infection rates and overall 
tolerance. Tolerance of Smoflipid was monitored by assessing essential fatty acid panel (with 
specific focus on the triene:tetraene ratio), glucose levels (Fasting Glucose and Hemoglobin 
A1C) and lipid panel (total cholesterol and triglycerides levels). These values assisted in 
determining appropriate dosage for creating a standard protocol for Smoflipid.  
Methods 
This research study consisted of six female and seven male outpatient children (n=13) 
with a mean age of 8.1±4.2 years. Age ranged from six-months to seventeen years of age.To be 
included in the study, participants must have either have finished 6 months of Smoflipid or are 
currently taking Smoflipid, be pediatric patients from 6 months to 21 years of age with intestinal 
failure, receiving home parenteral nutrition (PN) or total parenteral nutrition (TPN) and followed 
by Pediatric TPN Clinic. There was no exclusion criteria.     
The Institutional Review Board of Loma Linda University approved all methods and 
procedures. Risks of this study included a possible breach of confidentiality. Although patients 
may not personally benefit from this study, their participation may help practitioners see if 
Smoflipid improves intestinal failure and assist in establishing a standard protocol for Loma 
Linda University Children’s Hospital. 
An electronic medical record (EMR) review was conducted on patients who currently 
received Smoflipid emulsion or have finished six-months of Smoflipid from 2016 to 2018. EMR 
information was accessed via one computer at Loma Linda University Children’s Hospital 
through the electronic record program titled Loma Linda Electronic Access Portal (LLEAP). 
Routine lab values for patients were completed monthly for all patients on TPN.  Lab values 
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were examined three times: before the start of Smoflipid, at three-months and again at the end of 
six-months of Smoflipid. Hemoglobin A1C, triene-tetraene ratios and serum triglyceride levels 
were routinely measured for patients. Hemoglobin A1C was measured one-week prior to 
Smoflipid initiation and every three-months after. Essential fatty acid status was assessed by the 
triene-tetraene ratio and these values were obtained before initiation of Smoflipid and every six-
months after initiation. Blood glucose measurements were monitored closely when undergoing 
Smoflipid infusions.  
Data obtained from the electronic chart review consisted of age, gender, anthropometrics 
(weight, length/height, BMI), primary diagnosis/cause of TPN dependency, length of time on 
Smoflipid and % of total calories provided by TPN. Lab values assessed included alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, hemoglobin A1C, 
fasting blood glucose, total cholesterol, serum triglycerides and essential fatty acid panel with 
specific focus on the triene:tetraene ratio. 
            A prospective chart review was conducted at the Loma Linda University Children’s 
Hospital. Student investigators obtained access to LLEAP and were instructed on which patients 
to include in the study. Patient charts were divided equally among student investigators and 
follow-up values were conducted by the original assigned student investigator. 
To ensure reliability of the data collection process, an inter-rater reliability system was 
utilized. One student investigator recorded data from their assigned patient charts. Another 
student investigator also collected data from the same assigned patients. The recorded data was 
compared. This ensured a level of consensus among raters. 
Upon entering the study, a unique study number was assigned to each patient in 
alignment with a coding system to help organize patient information and protect personal 
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information. The master code key linking the study ID to participant names was only accessible 
to the primary investigator and co-investigators. This master code key was kept electronically on 
a single password protected University desktop computer inside a locked office within a locked 
building within Dr. Khiet Ngo’s office in Room A1110A at Loma Linda University Medical 
Center Coleman Pavilion. In the event there was loss of electronic data, a hardcopy of this code 
was maintained in the same secure office.  Data will be kept for 10 years after completion of the 
study in the event there are questions raised after the results are published in which having 
original data will help provide the answer. All data was recorded on an excel spreadsheet and 
other notes was made in a computer file.  Lab values were examined three times: before the start 
of Smoflipid, at the three-month of Smoflipid and at the end of six-months of Smoflipid. Data 
collection was composed of age, gender, primary diagnosis/cause of TPN dependency, 
anthropometrics (i.e. weight, length/height and BMI), lab values (i.e. liver enzymes (ALT/AST), 
total bilirubin, lipid panel (total cholesterol and triglycerides), essential fatty acid panel 
(triene:tetraene), hemoglobin A1C, and fasting glucose), number of days on Smoflipid,% 
dextrose and % protein provided by TPN, total grams/day and grams/kg of protein and 
carbohydrates provided by TPN, glucose Infusion Rate, Smoflipid cycle (hr/day), current 
Smoflipid rate (ml/hr) and maximum Smoflipid rate (ml/kg/hr), number of hospitalizations, and 
number of TPN central line infections.  
A Mixed Model was conducted to measure the changes in values, before and after 
treatment. Data consists of quantitative variables. These were classified as continuous and 
summarized by calculating the mean and standard deviation for both pre-measurement (one-
month prior the start of Smoflipid and post-measurement (after three-months and six-months of 
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Smoflipid). As there were random missing data values, The Mixed Model was used to handle 
these missing data values and provide unbiased estimates of the means.  
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Results 
Table 1. Mean (SD) of Liver Enzymes (ALT, AST) and Total Bilirubin Levels During the Six-
Months on Smoflipid Emulsion (N=13). 
 
Results indicated that Smoflipid led to an overall decrease in alanine transaminase (ALT) 
and aspartate transaminase (AST) values, after the three-month and six-month period. From the 
initiation of Smoflipid emulsion, there was a 26.9% decrease (108.2 U/L to 79.2 U/L) in ALT at 
three-months and a 23.2% decrease (108.2 U/L to 83.2U/L) at six-months (Table 1) (p=0.247). 
In terms of AST values, there was an 8.8% decrease (79.4 U/L to 70.6 U/L) at three-months and 
an 8.3% decrease (79.4 U/L to 71.1 U/L) at six-months (Table 1) (p=0.741). With respect to total 
bilirubin, there was a slight increase (0.85 mg/dL to 0.88mg/dL) of 3.6% at three-months and 
8.3% increase (0.85 mg/dL to 0.92 mg/dL) at six months (Table 1) (p=0.386). Over the past six-
months, Smoflipid did not have a statistical significant impact on ALT, AST and total bilirubin. 
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Table 2. Mean (SD) of BMI, Central Line Infection Rates, Hemoglobin A1C, Total Cholesterol, 
Glucose and Triglycerides During the Six-Months on Smoflipid Emulsion (N=13). 
 
As illustrated in Table 2, results showed that Smoflipid did not yield a statistical 
significant result overtime with respect to reducing BMI (p = 0.075), fasting glucose (p=0.171), 
total cholesterol (p = 0.906), and triglycerides (p = 0.104). Smoflipid yielded a statistically 
significant impact on TPN central line infection rates for five participants in the study (p=0.032), 
and exhibited a decrease in TPN central line infection rates of 80.7%. Regarding hemoglobin 
A1C, Smoflipid yielded a decrease of 17.3% (p=0.001), at the six month period in three 
participants. A 2.6% decrease was observed during the three-month period in six participants. 
Lastly, in regards to measuring tolerance of Smoflipid by monitoring essential fatty acid 
deficiencies through examining triene-tetraene ratios, values remained within the normal limits 
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of 0.013 to 0.050.  Mean average values of  the triene:tetraene ratio values were measured at 0.03 
at three-months in ten participants and 0.04 in five participants at six-months (p=0.001) (Figure 
1). There were not any indications of essential fatty acid deficiencies among participants in this 
study. Sample size of secondary outcomes fluctuated with each time measurement, throughout 
the study, due to the availability of data. 
 
Figure 1. Mean Triene:Tetraene Ratio (Normal Limit Ranges: 0.013-0.050) During Six-Months 
of Smoflipid Emulsion.  
Discussion 
Smoflipid emulsion is a new treatment that may be a beneficial alternative to the standard 
soybean-based lipid emulsion. The primary outcome of this study examined the effectiveness of 
Smoflipid on improving liver enzymes (AST and ALT) and total bilirubin levels on home-
dependent pediatric patients with intestinal failure related parenteral nutrition associated liver 
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disease (PNALD). In this study, Smoflipid was well-tolerated among most of the pediatric 
patients. Consistent with the present findings, Goulet et al.22 also reported that Smoflipid was 
well-tolerated and safe among pediatric patients receiving home TPN. In regards to liver 
enzymes, there was not any significant impact found in the reduction of AST and ALT. Research 
literature reports inconsistent results with Smoflipid and its effect on reducing liver enzymes.22,23 
In a randomized, controlled, double-blind, multicenter study among adult patient patients with 
intestinal failure, Klek et al.23 reported that the use of Smoflipid had significantly decreased the 
ALT and AST levels after the treatment period. Conversely, a study by Goulet et al.,22 conducted 
on the pediatric population, did not observe any significant difference in the reduction of liver 
enzymes. It is important to note, in our study, there was a decreasing trend in AST and ALT 
values. After the six-month of Smoflipid therapy, AST and ALT values were lower than their 
respective values at baseline levels. Thus, this suggests that Smoflipid may yield potential 
clinical biochemical effects in reducing elevated liver enzymes associated with PNALD.  
Furthermore,  Calkins, et al.24 examined the effects of replacing intravenous (IV) soybean 
oil with fish oil, with the goal of ameliorating cholestasis. After six months, there were 
reductions in direct and total bilirubin.24 As this study used pure fish oil, it is highly plausible 
that fish oil may yield different effects compared to mixed emulsion like Smoflipid.24 Results on 
using a mixed lipid emulsion in treating and preventing intestinal failure associated liver disease 
(IFALD) remains conflicting. Furthermore, a randomized control trial by Diamond et al.25 
compared patients on Smoflipid and Intralipid. Results demonstrated that Smoflipid was linked 
with decreasing serum bilirubin.25 Inconsistent with the findings of current literature of 
Smoflipid decreasing bilirubin levels, our study did not exhibited any reduction in bilirubin. 
Overall, there was a slight increase in total bilirubin trends among pediatric patients on 
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Smoflipid. We suggest that this slight increase in bilirubin may be attributed to the observational 
nature of the study and the small and heterogeneous nature of the sample size.  
Secondary outcomes examined Smoflipid and its effect on sustaining growth, reducing 
TPN central line infection rates and overall tolerance through monitoring essential fatty acid 
panel (with specific focus on the triene:tetraene ratio), glucose levels (Fasting Glucose and 
Hemoglobin A1C) and lipid panel (total cholesterol and triglycerides levels). In our study, 
Smoflipid was tolerated well among the pediatric patients without any side effects, and long-term 
use showed to decrease infection rates and hemoglobin A1C, which was beneficial for the 
patients who are on Smoflipid. Other studies such as Goulet et al.,22 Diamond et al.,24 and 
Calkins et al.25 have not shown decreased hemoglobin A1C in pediatric patients. However, a 
review by Montori et al,26 demonstrated that the addition of fish oil in PN formula lowered 
triglycerides and LDL levels, which in turn improved insulin sensitivity. Recent research by 
Riserus et al.27 suggested elevated lipid levels in the blood may block insulin signaling cycles to 
the cell. Thus, lipid reduction may improve glucose utilization.27 A significant impact in 
reduction in hemoglobin A1C was an unexpected finding. However, it is crucial to take in 
account that this is exploratory data. Therefore, clinical decisions cannot be made at this time on 
the effects of Smoflipid on hemoglobin A1C. A systematic review and meta-analysis by 
Manzanares et al.28 examined infection rates in five randomized controlled clinical trials, within 
the critically-ill population, on the use of fish oil-based lipid emulsions in PN formulas.28 All 
five trials found the fish oil based lipid emulsions did not exhibit any effect on mortality and had 
a statistically significant effect on the reduction of infection rates.28 However, the impact of fish-
oil based lipid emulsions in reducing infection rates remains inconclusive. In other randomized 
controlled trials, assessed by Manzanares et al.,28 Smoflipid had the same effect on infection 
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rates as other lipid emulsions. This generates new questions and sparks future areas of research 
with the effects of Smoflipid on infection rates and hemoglobin A1C. Furthermore, consistent 
with other findings, Smoflipid did not cause any complications in regards to growth, total 
cholesterol, triglycerides and essential fatty acid status. Parallel to the findings of Pichler, J., et 
al.,29 this study compared a new IV lipid emulsion (Lipofundin: MCT and soybean oil) and a 
mixed IV lipid emulsion (Smoflipid). There were no differences in respect to infection rates, 
total cholesterol, and serum triglycerides, between the the Lipofundin and Smoflipid groups. No 
side effects were displayed in the children on Smoflipid or Lipofundin, but a significant 
nutritional improvement weight gain was reported in both groups.28 Although it remains unclear 
as to why there were not any differences found, regarding infection rates, total cholesterol, and 
serum triglycerides, when comparing soybean-based and fish oil-based lipid emulsions, this 
demonstrates that a mixed lipid emulsions, like Smoflipid, can potentially be safe, well-tolerated 
and meet the nutrient needs within the parenteral nutrition dependent population. The anti-
inflammatory nature of the reduced phytosterol content, improved omega-6 to omega-3 ratio and 
increased alpha-tocopherol, supports the advantages of using a fish oil-based lipid emulsion over 
the standard soybean-based lipid emulsion.  
Complications during the study included one twelve year-old participant with severe 
hyperglycemia, upon the start of Smoflipid. Although this phenomenon is rare, there has been 
incidences in preterm infants where hyperglycemia was a result of the introduction of PN 
formula. It is speculated that this rise in serum glucose level is due to the increase in FFAs as a 
result of lowering the amount of glucose being utilized peripherally or decreasing insulin 
suppression of glucose production from the liver.26 One common cause of hyperglycemia 
involve high dextrose infusion rates. It is common for rebound hypoglycemia to transpire after 
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an abruptly stopping parenteral nutrition.30 To prevent glucose and insulin abnormalities, the 
cycle of parenteral nutrition is advanced over two hours and subsequently tapered off over two 
hours.30 To monitor blood glucose levels, these values are checked at peak infusion rate and 
again post 30-minutes after stopping parenteral nutrition.30 In the one patient that experienced 
severe hyperglycemia, extensive measures were taken to eliminate other confounding factors that 
may be eliciting abnormal blood glucose levels. Home diet, medications, glucose infusion rate, 
time of when glucose levels were assessed and overall nutrition support regimen remained the 
same. The only modification to the program was switching from Intralipid to Smoflipid. One 
possible theory on the correlation of hyperglycemia and initiation of Smoflipid pertains to the 
interplay of the gut microbiome on parenteral nutrition dependent patients. Very few studies 
exist on examining the intestinal microbiota in TPN-dependent pediatric patients with short 
bowel syndrome (SBS).31,32,33 Lila et al.31 and Cahova et al.32 examined the gut microbiome and 
the ramifications of parenteral nutrition in initiating gut dysbiosis, impaired gut barrier function 
and inflammation. Lilja et al.31 was one of the first human studies exploring this role and 
reported that pediatric patients with SBS have “microbial dysbiosis” which lowers the diversity 
bacterial diversity in their intestinal microbiome. This may be the culprit in mitigating pro-
inflammatory bowel diseases.31 A review by Cahova et al.32 reports that there is a complex and 
multifaceted interplay of how parenteral nutrition may detrimentally elicit dysbiosis, which could 
also be one of the precipitating factors in the development of PNALD.32 Interestingly, in an in-
vitro study on neonatal pigs conducted by Lavalle et al.,33 they compared the microbiome 
response of Smoflipid and the standard soybean-based lipid emulsion. Findings reported that 
different lipid emulsions had various effects on gut microbiota diversity and gut barrier 
function.33 Although the exact mechanism has not been identified, long-chain omega-3 fatty 
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acids, from Smoflipid, facilitated in improving the bacterial microbiota interactions on the 
intestinal mucosa.33 Unfortunately, to date, there is not any research examining how glucose 
metabolism is affected by these mixed lipid emulsions. However, it is plausible that the gut 
microbiome may play a role in glucose and insulin metabolism and homeostasis. More research 
is needed on the interplay between the gut microbiome on metabolism, in parenteral nutrition 
dependent patients. 
Another complication involved a five-year old participant who was presented with 
epistaxis at the end of the six-months and was subsequently discontinued from Smoflipid 
therapy. One explanation of epistaxis includes the omega-3 fatty acid component of fish oil in 
Smoflipid. Omega-3 fatty acids have lower prothrombotic properties and are often been 
employed in preventative measures for coronary heart disease.34 However, their propensity to 
decrease platelet aggregation raises concern for prolonged bleeding times and increased risk for 
bleed complications.34,35 In-vitro studies demonstrate that omega-3 fatty acids inhibit the 
cyclooxygenase (COX) enzyme which directly attenuate the production of thromboxane A2 from 
arachidonic acid.35 This metabolic pathway diminishes the synthesis of platelet-activation factors 
which may attribute omega-3 fatty acids to enhanced bleeding tendencies.35 However, studies 
correlating the incidence with omega-3 fatty acids in significantly eliciting bleeding 
complications remains inconclusive.35 We suggest the omega-3 fatty acid content of Smoflipid 
may be one of many factors that could have led to this epistaxis complication, in this participant.  
 Limitations of this study include the heterogeneous nature, size of sample and age. As 
participants varied on clinical diagnosis, nutrition support regimen and age, this may be why 
there was no difference found on the effects of Smoflipid on liver enzymes and total bilirubin 
levels. To observe a true representation of the effect of Smoflipid, all participants should yield a 
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similar background in regards to age, clinical diagnosis, nutrition support regimen. Moreover, 
this study was purely an observational study and yielded a broad age group from six-months to 
seventeen years of age (mean age of 8.1±4.2 years). The age range in this study were older than 
the typical age range for when Smoflipid is typically employed. Smoflipid is normally seen 
implemented in neonatal intensive care units (NICU) preterm infants of younger than six-months 
of age. As age may play a factor in the effectiveness of Smoflipid, it may be plausible that 
Smoflipid may be more effective among infants of less than six-months of age. There may be a 
threshold of effectiveness once a certain age is reach. This could explain why Smoflipid may not 
achieve a significant impact on older pediatric patients with intestinal failure related PNALD. 
Future areas of research include examining the effects of Smoflipid beyond the NICU arena and 
investigating the critical period of when Smoflipid will be most effective. Another limitation 
includes the management and handling of missing laboratory data values. In some participants, 
compliance of obtaining routine lab values were not followed per protocol. A Mixed Model 
approach was the statistical approach to take to handle missing laboratory data values. However, 
obtaining all lab values can provide a better understanding on the true effects of Smoflipid. 
Dosing of Smoflipid is another confounding factor for this study. The maximum infusion rate of 
Smoflipid, per Food Drug Administration (FDA) dosage protocol, is at 0.5ml/kg/hour. Some 
participants were receiving Smoflipid treatments from various institutions and there was a 
variability in the dosing of Smoflipid infusion. Two participants had Smoflipid doses that went 
slightly beyond the maximum infusion rate. Furthermore, understanding the underlying 
mechanism of the action of the dose and overall lipid emulsion composition in it relationship of 
ameliorating intestinal failure related PNALD is limited.  
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Continuance of Smoflipid use over a longer time frame may be helpful for future research 
studies to see if there are further improvements. Due to the unique complications of each patient 
on long term TPN, a longer time frame for the study would be able to account for any 
hospitalizations that occured and allow for lab values to be normalized before being recorded. 
Furthermore, a larger and homogenous sample size is crucial to truly assess the effects of 
Smoflipid. Future research on assessing the effects of various Smoflipid dosage is also beneficial 
to understand its relationship with ameliorating PNALD. Another area of future research that 
shows potential is comparing the impact of pure fish oil lipid emulsion (Omegavan) versus 
mixed lipid emulsion (Smoflipid). According to Calkins et al.,24 mixed lipid emulsions like 
Smoflipid may be perceived as “more balanced.” However, research supporting the relationship 
between Smoflipid in preventing intestinal failure related PNALD remains conflicting. It will 
also beneficial to examine the optimal time period for when Smoflipid will be most effective in 
preventing or reducing intestinal failure related PNALD. Understanding complications of 
epistaxis and the effects of the omega-3 fatty acids in fish oil-base emulsions is also another 
venue for research. A strong and necessary area of potential research is measuring the effects of 
the microbiome on parenteral nutrition-dependent patients and its role in nutrient metabolism. 
Severe hyperglycemia was observed in one patient. After ruling out other factors that may have 
been contributing to the hyperglycemic response from Smoflipid, it will prove useful to 
understand how gut dysbiosis, in parenteral nutrition dependent patients, mitigates inflammatory 
pathways and affect overall nutrient metabolism and gut barrier function. Lastly, Smoflipid’s 
impact on hemoglobin A1C and infection rates warrants future research. 
Conclusion 
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Parenteral nutrition (PN) is critical in meeting the nutritional needs of patient who are 
unable to digest or absorb nutrients, enterally or orally. As Smoflipid yields a lower n-6:n-3 ratio, 
lower phytosterol content and higher alpha-tocopherol content, this may reduce lipid 
peroxidation and prevent or reduce further damage to the liver. An increasing body of evidence 
supports the usage of Smoflipid in preventing or reducing complications associated with 
PNALD. Furthermore, the higher n-3 fatty acid content may be beneficial in mitigating anti-
inflammatory eicosanoid pathways.  
Smoflipid shows promise in improving the quality of life by reducing TPN central line 
infections rates and hemoglobin A1C. Although data demonstrated statistically significant results 
in the reduction of central line infections and hemoglobin A1C, clinical decisions can not be 
made at this time on whether Smoflipid played a direct effect with these findings. Future 
research is needed to explore this relationship. Furthermore, it is important to note a decreasing 
trend in the overall mean percent change of liver enzymes (AST and ALT). Despite the fact that 
the reduction of liver enzymes results were not statistically significant, Smoflipid may yield 
potential clinical biochemical effects in reducing elevated liver enzymes associated with 
PNALD. In all, Smoflipid may be a beneficial alternative to the standard soybean-based lipid 
emulsion. It may enhance the quality of life by preventing or reducing complications associated 
with PNALD through improving liver function, sustaining growth, reducing inflammation and 
reducing TPN infection rates. Additional research is needed to further examine the effectiveness 
of Smoflipid on the liver to facilitate in establishing a standard protocol. 
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